中/EN
中文繁體
English
Investor Relations
IR Home
Corporate Overview
Financial Highlights
Financial Reports
ESG Reports
Regulatory Filings
Press Releases
Company Presentations
Stock Quotes & Charts
Analyst Coverage
FAQs
IR Contact
Corporate
Investor Relations
IR Home
Corporate Overview
Financial Highlights
Financial Reports
ESG Reports
Regulatory Filings
Announcements & Notices
Circulars
Returns on Share Capital
Listing Documents
Constitutional Documents
Press Releases
Company
Presentations
Stock Quotes &
Charts
Analyst Coverage
FAQs
IR Contact
Announcements & Notices
2026
Please select
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
FEB
09
THE GROUP'S PRODUCT ROXITHROMYCIN CAPSULES PASSED THE CONSISTENCY EVALUATION
FEB
03
APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OSA
JAN
28
FDA APPROVAL OF IND FOR GROUP'S PRODUCT TUL108 FOR INJECTION
